The demonstration that multiple subtypes of tau are liberated during pneumonia, and that these different subtypes may be responsible for unique clinical symptoms observed because of pneumonia, highlights the complexity of developing clinical treatments for addressing the long-term deleterious effects of pneumonia. The gene discussed is MAPT; the disease is susceptibility to pneumonia measurement.